Anti-inflammatory benefits of semaglutide: State of the art.
J Clin Transl Endocrinol · 2024
Last updated 2026-08-28Semaglutide, a GLP-1 drug used to treat diabetes, may also help reduce chronic inflammation linked to the disease. Research suggests it can lower high levels of inflammatory markers, though the exact way it works is still unclear. Studies indicate it could improve blood sugar control while providing additional anti-inflammatory benefits.
AI summary of the abstract below.
| Journal | J Clin Transl Endocrinol, 2024 |
|---|---|
| Citations | 49 |
| Relative citation ratio | 8.92 |
| NIH percentile | 97 |
| Molecules | semaglutide |
Abstract
Individuals with diabetes often have chronic inflammation and high levels of inflammatory cytokines, leading to insulin resistance and complications. Anti-inflammatory agents are proposed to prevent these issues, including using antidiabetic medications with anti-inflammatory properties like semaglutide, a GLP-1 analogue. Semaglutide not only lowers glucose but also shows potential anti-inflammatory effects. Studies suggest it can modulate inflammatory responses and benefit those with diabetes. However, the exact mechanisms of its anti-inflammatory effects are not fully understood. This review aims to discuss the latest findings on semaglutide's anti-inflammatory effects and the potential pathways involved.
Verbatim abstract via PubMed 38576822 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.